Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis by Mattsson, N et al.
ARTICLE
Received 18 Aug 2015 | Accepted 2 Feb 2016 | Published 7 Mar 2016
Increased amyloidogenic APP processing in APOE
e4-negative individuals with cerebral b-amyloidosis
Niklas Mattsson1,2,3, Philip S. Insel1,4, Sebastian Palmqvist1,3, Erik Stomrud1,2, Danielle van Westen5,6,
Lennart Minthon1,2, Henrik Zetterberg7,8, Kaj Blennow8 & Oskar Hansson1,2
Increased APP (amyloid precursor protein) processing causes b-amyloid (Ab) accumulation
in autosomal dominant Alzheimer’s disease (AD), but it is unclear if it also affects sporadic
Ab accumulation. We tested healthy controls and patients with mild cognitive symptoms
(N¼ 331) in the BioFINDER study, using cerebrospinal ﬂuid (CSF) Ab40 as a surrogate
for amyloidogenic APP processing. We ﬁnd that levels of brain Ab ﬁbrils (measured by
18F-ﬂutemetamol PET) are independently associated with high CSF Ab40 (Po0.001) and
APOE e4 (Po0.001). The association between CSF Ab40 and brain Ab is stronger in
APOE e4-negative than in positive people (P¼0.0080). The results are similar for CSF Ab38
and for a combination of CSF Ab38 and CSF Ab40. In conclusion, sporadic Ab accumulation
may be partly associated with increased amyloidogenic APP production, especially in
APOE e4-negative subjects. The risk for sporadic AD may consequently depend on increased
Ab production, in addition to decreased Ab clearance.
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B
rain accumulation of amyloid b (Ab) is a hallmark of
Alzheimer’s disease (AD) which may precede dementia by
up to two decades1–3 and be quantiﬁed by cerebrospinal
ﬂuid (CSF) biomarkers or positron emission tomography (PET)
imaging4,5. Ab accumulation is thought to be caused by an
imbalance of Ab production and clearance from the brain6.
The APOE e4 allele is the main genetic susceptibility factor for
late-onset AD and sporadic Ab pathology7. This is likely because
the APOE e4 gene product apoE4 has reduced capacity to clear
Ab peptides from the brain8. However, Ab accumulation also
occurs in the absence of APOE e4 (ref. 7) and B40–50% of AD
patients lack the APOE e4 allele9. In autosomal dominant forms
of AD, Ab pathology is believed to be caused by increased
amyloidogenic processing of APP (amyloid precursor protein),
that is, increased Ab production10 but variations in APP
processing have not been thoroughly explored as risk factors in
‘sporadic’ AD. Using a large cohort of non-demented subjects, the
aim of this study was to test if APOE e4 and biomarker surrogates
of amyloidogenic APP processing were independently associated
with brain Ab accumulation. We used CSF levels of Ab40 to
estimate amyloidogenic APP processing. The rationale for this
was that Ab40 is a major Ab isoforms produced by neurons by
concerted b- and g-secretase cleavages of APP (the same
processing pathway that results in Ab42)11 but is generally not
related to Ab plaque pathology (in contrast to CSF Ab42, which is
reduced in the presence of Ab plaques12). Note that previous
studies testing the correlation between CSF Ab40 and PET Ab
have not co-varied for the presence of APOE e4. We hypothesized
that there would be independent correlations between Ab
accumulation and the predictors APOE e4 and CSF Ab40, and
that increased amyloidogenic APP processing would be related to
Ab accumulation mainly in APOE e4-negative subjects. We also
hypothesized that CSF Ab40 would not be associated with APOE
e4 (that is, CSF Ab40 would not be affected by apoE4-mediated
impaired Ab clearance). Finally, we hypothesized to see similar
results when using CSF Ab38 instead of CSF Ab40 to estimate
amyloidogenic APP processing.
Our results conﬁrmed our hypothesis. We show that 18F-
ﬂutemetamol PET levels are independently associated with
high CSF Ab40 (Po0.001) and APOE e4 (Po0.001) and that
the association between CSF Ab40 and brain Ab is stronger in
APOE e4-negative than in positive people (P¼ 0.0080).
The results are similar when using CSF Ab38 or a combination
of CSF Ab38 and CSF Ab40 to estimate amyloidogenic APP
production. We conclude that sporadic Ab accumulation may be
partly associated with increased amyloidogenic APP production,
especially in APOE e4-negative subjects. Thus, the risk for
sporadic AD may partly depend on increased Ab production, in
addition to decreased Ab clearance.
Results
Cohort characteristics. The cohort consisted of 331 participants
(cognitively normal controls (CN) 121, subjective cognitive
decline (SCD) 102 and mild cognitive impairment (MCI) 108).
Demographics and data on cognition and biomarkers are
summarized in Table 1 (see Table 2 for demographics stratiﬁed by
APOE status). In sum, APOE e4 positivity was more common in
SCD and MCI than in CN, CSF Ab42 levels were lower in MCI
compared with the other groups, and the frequency of PET Ab
positivity was lowest in CN and highest in MCI. CSF Ab38 and
CSF Ab40 did not differ between the diagnostic groups. APOE e4
was not associated with CSF Ab40 or with CSF Ab38 (Fig. 1). The
lack of association between APOE e4 and CSF Ab40 and CSF
Ab38 supports our assumption that these CSF Ab peptides are
unaffected by apoE4-mediated clearance of Ab.
APOE e4 and high CSF Ab40 independently predict PET Ab.
Figure 2 shows the observed PET Ab and CSF Ab40 data, with
estimated slopes in the APOE e4-positive and -negative groups. In
a linear regression model with PET Ab as the dependent variable,
high levels of CSF Ab40 (b¼ 1.05 10 4, Po0.001),
APOE e4-positivity (b¼ 0.406, Po0.001) and the interaction
between APOE e4 and CSF Ab40 (b¼  5.61 10 5,
P¼ 0.0080) were all signiﬁcant predictors of continuous PET Ab.
Note that since APOE e4 and CSF Ab40 were both included as
predictors the main effect of CSF Ab40 indicates the effect within
APOE e4-negative subjects. The signiﬁcant interaction between
CSF Ab40 and APOE e4 indicates that the correlation between
CSF Ab40 and brain Ab was stronger in APOE e4-negative than
in positive people (as seen in Fig. 2). The correlation between CSF
Ab40 and PET Ab in the APOE e4-positive group was weaker
than in the APOE e4-negative group, but remained signiﬁcant
(b¼ 0.485 10 4, P¼ 0.010). The results support the
hypotheses that high CSF Ab40 and APOE e4 are independent
predictors of PET Ab, and that the relationship between CSF
Ab40 and PET Ab varies with APOE e4 carrier status. As
expected, CSF Ab42 was a signiﬁcant covariate (low CSF Ab42
was correlated with PET Ab, b¼  0.00120, Po0.001), but CSF
Ab40, APOE e4 and the interaction between CSF Ab40 and
Table 1 | Demographics.
CN SCD MCI All P value
N 121 102 108 331
Age (y) 73.7 (4.5) 70.2 (5.6) 71.2 (5.6) 71.8 (5.4) o0.001
Sex (F) 63% 51% 40% 52% 0.0023
Education (y) 11.5 (3.28) 12.7 (3.28) 11.3 (3.38) 11.8 (3.39) 0.0038
MMSE (points) 29.0 (0.92) 28.5 (1.47) 27.2 (1.69) 28.3 (1.57) o0.001
ADAS-cog, delayed recall (points) 2.1 (2.0) 3.3 (2.2) 6.4 (2.2) 3.9 (2.8) o0.001
APOE e4 (% þ ) 28% 42% 43% 37% 0.028
PET Ab (% þ ) 19% 37% 61% 38% o0.001
PET Ab (SUVR) 1.30 (0.28) 1.41 (0.38) 1.70 (0.53) 1.46 (0.44) o0.001
CSF Ab38 (ng l 1) 1,742 (404) 1,722 (421) 1,686 (421) 1,718 (414) 0.51
CSF Ab40 (ng l 1) 4,510 (1526) 4,893 (1852) 4,812 (1809) 4,727 (1728) 0.35
CSF Ab42 (ng l 1) 538 (187) 584 (251) 475 (216) 532 (221) 0.0031
ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; CN, cognitively normal; CSF, cerebrospinal ﬂuid; MCI, mild cognitive impairment; MMSE, mini-mental state examination;
PET, positron emission tomography; SCD, subjective cognitive decline; SUVR, standardized uptake value ratio.
Continuous data are mean (s.d.). APOE e4þ is deﬁned as at least one e4 allele. PET Ab positivity is deﬁned as41.42 SUVR (ref. 13). MMSE ranges from 0 to 30. ADAS-cog delayed recall ranges from 0
to 10 (word list learning test from the ADAS-cog battery, points indicate number of missed items). P values are for comparisons between diagnostic groups (using Kruskal–Wallis test for continuous
variables and X2-test for categorical variables).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10918
2 NATURE COMMUNICATIONS | 7:10918 | DOI: 10.1038/ncomms10918 | www.nature.com/naturecommunications
APOE e4 remained signiﬁcant also when not adjusting for CSF
Ab42 (CSF Ab40: P¼ 0.0089; APOE e4: Po0.001; interaction:
P¼ 0.026). Age (b¼ 0.0082, P¼ 0.0094) and diagnosis
(SCD, b¼ 0.137, P¼ 0.0011; MCI, b¼ 0.299, Po0.001) were also
signiﬁcant predictors of PET Ab, but sex was not (P¼ 0.23).
White matter lesions (WML) were evaluated as a covariate, but
were not signiﬁcant (P¼ 0.68) and were therefore excluded from
the ﬁnal model. We also evaluated plasma levels of Ab40 as a
covariate to exclude the possibility that the results depended on
peripheral APP processing. Plasma Ab40 was not a signiﬁcant
covariate (P¼ 0.99) and including it in the model did not change
the other estimates.
To further examine if clinically signiﬁcant Ab accumulation
(deﬁned as a composite standardized uptake value ratio (SUVR)
41.42 (ref. 13) was associated with CSF Ab40, we evaluated a
logistic regression model with PET Ab positivity as the dependent
variable. CSF Ab40 (log odds¼ 9.18 10 4, Po0.001) was a
signiﬁcant predictor in this model but APOE e4 (P¼ 0.13), and
the interaction between CSF Ab40 and APOE e4 were not
(P¼ 0.73). Age and sex (P¼ 0.13–0.14) were not signiﬁcant but
CSF Ab42 (Po0.001) and diagnosis (SCD, P¼ 0.0016; MCI,
Po0.001) remained signiﬁcant covariates. When CSF Ab42 was
excluded from the model, CSF Ab40 (P¼ 0.014) and APOE e4
(Po0.001) were both signiﬁcant predictors of PET Ab positivity.
CSF Ab38 as an independent predictor of PET Ab. To
corroborate our ﬁndings, we repeated the analyses using CSF
Ab38 instead of CSF Ab40, with very similar results. When
predicting continuous PET Ab, the effects of CSF Ab38
(b¼ 4.04 10 4, Po0.001), APOE e4 (b¼ 0.72, Po0.001)
and the interaction between APOE e4 and CSF Ab38
(b¼  3.40 10 4, Po0.001) were all signiﬁcant, and CSF
Ab42 was a signiﬁcant covariate (b¼  0.00112, Po0.001).
CSF Ab38 (P¼ 0.017), APOE e4 (Po0.001) and the interaction
between APOE e4 and CSF Ab38 (P¼ 0.015) remained
signiﬁcant when removing CSF Ab42 from the model. When
predicting PET Ab positivity using logistic regression, CSF Ab38
(log odds¼ 0.00332, Po0.001) and APOE e4 (log odds¼ 4.47,
P¼ 0.0075) were independent predictors and there was a
tendency for signiﬁcant interaction between APOE e4 and CSF
Ab38 (P¼ 0.061). Again, CSF Ab42 was a signiﬁcant covariate
(log odds¼  0.0119, Po0.001).
We also used a combination of CSF Ab40 and CSF Ab38 based
on their molar amounts (CSF Ab, mol l 1). Again, the results were
very similar. When predicting continuous PET Ab, the effects of
CSF Ab (b¼ 3.70 108, Po0.001), APOE e4 (b¼ 0.470,
Po0.001) and the interaction between APOE e4 and CSF Ab
(b¼  2.20 108, P¼ 0.0030) were all signiﬁcant predictors. CSF
Ab42 remained a signiﬁcant covariate (b¼  0.00120, Po0.001).
CSF Ab (P¼ 0.0090), APOE e4 (Po0.001) and the interaction
between APOE e4 and CSF Ab (P¼ 0.021) remained signiﬁcant
when removing CSF Ab42 from the model. When predicting PET
Ab positivity using logistic regression, CSF Ab (log odds¼ 3.15
 109, Po0.001) was a signiﬁcant predictor and CSF Ab42
remained a signiﬁcant covariate (log odds¼  0.0129, Po0.001).
CSF Ab40 is highest in APOE e4 PET Abþ subjects. In a
linear regression model with CSF Ab40 as the dependent variable
and a four level combination of PET Ab and APOE as the
independent variable, the overall highest CSF Ab40 levels were
seen in the PET Abþ & APOE e4 group (b¼ 732, P¼ 0.015,
compared with the reference category PET Ab- & APOE e4 ,
Fig. 3). PET Abþ & APOE e4 subjects had 19% higher mean
level of CSF Ab40 (and 26% higher median level) compared with
PET Ab- & APOE e4 subjects. The model was adjusted for
WML (b¼  18.8, P¼ 0.00013), age (b¼ 46.1, P¼ 0.015), sex
(female sex, b¼  322, P¼ 0.094) and diagnostic group (SCD,
b¼ 570, P¼ 0.019; MCI, b¼ 421, P¼ 0.11). When also adjusting
for CSF Ab42 as a covariate the effect of PET Ab & APOE e4 was
even stronger, with higher CSF Ab40 in the PET Abþ & APOE
e4 group compared with PET Ab- & APOE e4 (Po0.001)
and PET Ab- & APOE e4þ (Po0.001) but no signiﬁcant
difference compared with the PET Abþ & APOE e4þ group
(P¼ 0.45).
Discussion
We tested the hypothesis that biomarker surrogates of
amyloidogenic APP processing (CSF Ab40 and Ab38) and APOE
e4 were independent predictors of brain Ab ﬁbril accumulation.
In accordance with our hypotheses, CSF Ab40 (and Ab38 in a
secondary analysis) and APOE e4 were independent predictors of
PET Ab, and the effect of CSF Ab40 was strongest in the APOE
e4-negative individuals. To our knowledge, this is the ﬁrst study
showing that increased Ab production are associated with
Table 2 | Demographics by diagnostic group and APOE e4.
CN SCD MCI All
N 121 102 108 331
APOE e4 APOE e4þ APOE e4 APOE e4þ APOE e4 APOE e4þ APOE e4 APOE e4þ
87 34 59 43 61 47 207 124
Age (y) 73.5 (4.4) 74.1 (4.7) 70.1 (6.0) 70.3 (5.0) 71.0 (6.1) 71.5 (5.0) 71.8 (5.6) 71.8 (5.1)
Sex (F) 63% 62% 53% 49% 41% 38% 54% 48%
Education (y) 11.6 (3.3) 11.5 (3.3) 12.9 (3.5) 12.4 (2.9) 11.3 (3.4) 11.3 (3.3) 11.9 (3.5) 11.7 (3.2)
MMSE (points) 29.0 (0.97) 29.2 (0.78) 28.4 (1.55) 28.6 (1.35) 27.2 (1.75) 27.2 (1.62) 28.3 (1.58) 28.2 (1.57)
ADAS-cog, delayed recall
(points)
2.2 (2.1) 1.7 (1.9) 3.2 (2.3) 3.5 (2.0) 6.0 (2.3) 6.9 (2.0) 3.6 (2.7) 4.3 (2.9)
PET Ab (% þ ) 10% 41% 20% 61% 38% 91% 21% 67%
PET Ab (SUVR) 1.22 (0.16) 1.48 (0.41) 1.27 (0.29) 1.59 (0.42) 1.51 (0.51) 1.95 (0.45) 1.32 (0.35) 1.70 (0.47)
CSF Ab38 (ng l 1) 1,741 (420) 1,742 (365) 1,735 (457) 1,705 (367) 1,670 (436) 1,707 (405) 1,719 (435) 1,716 (380)
CSF Ab40 (ng l 1) 4,573
(1,655)
4,348
(1,135)
5,076
(2,051)
4,643
(1,527)
4,792
(1,969)
4,838
(1,599)
4,781
(1,871)
4,636
(1,461)
CSF Ab42 (ng l 1) 571 (179) 454 (181) 673 (240) 462 (213) 559 (211) 365 (168) 596 (212) 423 (192)
ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; CN, cognitively normal; CSF, cerebrospinal ﬂiuid; MCI, mild cognitive impairment; MMSE, mini-mental state examination;
PET, or positron emission tomography; SCD, subjective cognitive decline; SUVR, standardized uptake value ratio.
Continuous data are mean (s.d.). APOE e4þ is deﬁned as at least one e4 allele. PET Ab positivity is deﬁned as41.42 SUVR (ref. 13).
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increased risk for sporadic brain Ab accumulation. These novel
results provide indirect evidence that brain Ab pathology in
humans may arise from two pathways, where one involves the
APOE e4 allele (likely causing reduced apoE4-mediated Ab42
clearance), and the other involves increased amyloidogenic
processing of APP. This may correspond to two pathways to
sporadic AD, namely reduced clearance and increased production
of Ab peptides.
The amyloid cascade hypothesis postulates that Ab pathology
arises due to an imbalance between Ab production and
clearance6. It has been suggested that sporadic AD is mainly
caused by poor clearance of peptides from the brain, whereas
autosomal dominant AD is mainly caused by increased Ab
production, especially the Ab42 variant. This is supported by a
metabolic labelling study showing reduced Ab clearance in
sporadic AD dementia14, and studies showing increased
amyloidogenic APP processing in early stages of autosomal
dominant AD10. The main cause of reduced Ab clearance in
sporadic AD is likely APOE e4, since the apoE4 protein isoform
has reduced capacity to clear Ab peptides compared with other
apoE isoforms8, although it is possible that APOE e4 may also
contribute to increased AD risk by other mechanisms, for
example, by affecting inﬂammation and neuronal repair15,16.
However, one APP gene polymorphism which reduces Ab
production is associated with reduced risk of AD in the general
population17, which provides genetic evidence that variations in
APP processing may also affect the risk for sporadic AD.
The main limitation of this paper was that we used an indirect
measure of APP processing, which was estimated by CSF Ab40.
The rationale for this approach was that Ab40 is a major Ab
isoform produced by neurons11, which is not directly inﬂuenced
by the presence of Ab plaque pathology12, and is not inﬂuenced
by APOE e4-mediated impaired Ab clearance. The later was
demonstrated by our ﬁnding that there was no overall difference
in CSF Ab40 depending on APOE e4 status (Fig. 1). Alterations in
CSF Ab40 are therefore more likely to reﬂect differences in
amyloidogenic APP processing rather than differences in Ab
clearance. However, we acknowledge that there may be variations
in APP processing that are not captured by CSF Ab40. We also
performed analyses using CSF Ab38 (another highly expressed
Ab isoform) and a combination of CSF Ab38 and CSF Ab40
(based on their molar amounts), with very similar results as when
using CSF Ab40 alone, which support our ﬁndings. A more direct
estimate of Ab production may be done by metabolic labelling14,
but such methods are liable to bias due to the longitudinal drift of
CSF biomarkers during continuous CSF sampling that depends
on sampling frequency and volume18. Another limitation is that
there may be other factors affecting CSF Ab40 besides variations
in APP processing. For example, reduced CSF Ab40 is associated
with chronic WML19, and WML may also be associated with Ab
pathology (although this is more common in MCI20 and AD
dementia20 than in non-demented people21). It is not clear if the
association between CSF Ab40 and WML is due to a direct link
between Ab production and WML or if lower CSF Ab40 levels
reﬂect reduced neuronal Ab secretion due to decreased brain
activity in the presence of WML. Importantly, our results
remained signiﬁcant when adjusting for WML. Theoretically,
CSF Ab40 could also be inﬂuenced by peripheral APP processing,
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Figure 2 | PETAb as a function of CSF Ab40 and APOE e4. Observed PET
and CSF Ab40 data. Slopes are modelled from a linear regression adjusted
for CSF Ab42, sex, age and diagnostic group. The shaded areas indicate
95% conﬁdence intervals for the slopes. The dotted line indicates a cutoff
for clinically signiﬁcant PET Ab load (1.42 SUVR). b-coefﬁcients (divided by
104) and P values for the slopes within APOE e4-positive and separately
for APOE e4-negative subjects are shown in the legend. The interaction
between CSF Ab40 and APOE e4 is signiﬁcant, indicating that the
correlation between CSF Ab40 and PET Ab differs by APOE e4 status
(P¼0.0080). The results did not change signiﬁcantly when removing
outliers (CSF Ab40410,000ng l 1).
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Figure 1 | CSF Ab38 and Ab40 in APOE e4- and APOE e4þ subjects.
Observed data for CSF Ab38 and CSF Ab40 by APOE e4 status. The
individual observations are overlaid on boxplots (thick lines are medians, box
limits are 25th and 75th percentiles). APOE e4 did not affect levels of CSF
Ab38 (Mann–Whitney U-test, P¼0.75; t-test, P¼0.95; linear regression
adjusted for age, sex and diagnosis, P¼0.99) or CSF Ab40 (Mann–Whitney
U-test, P¼0.84; t-test, P¼0.43; linear regression adjusted for age, sex and
diagnosis, P¼0.26). This supports the notion that CSF Ab38 and Ab40 are
unaffected by APOE e4-mediated changes in Ab clearance.
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but our results were stable when adjusting for plasma Ab40,
suggesting that the effects did not depend on peripheral APP
processing. We did not measure all other possible factors
besides increased amyloidogenic APP that may contribute to
Ab deposition in APOE e4-negative subjects. For example, other
AD risk genes (including CLU and CR1) may impact Ab
clearance in APOE e4-negative subjects22. We included several
different diagnostic groups, including a SCD group. We noted
that the frequency of Ab positivity in our SCD subjects (37%) was
higher than in a recent large meta-analysis by Jansen et al.3
where B22% of SCD subjects were Ab-positive, compared with
B25% of CN subjects. The reason for this difference is not clear,
but we noted that our SCD subjects were on average 6 years older
than the Jansen subjects, which may contribute to higher
frequency of Ab pathology. Furthermore, all our SCD subjects
were referred to specialized memory clinics because of cognitive
symptoms, while some of the Jansen SCD subjects may have been
seen at other health care facilities, opening for the possibility that
they had less severe complaints than the SCD subjects in our
study. Another recent study on PET Ab positivity in memory
clinic SCD subjects found that 57% of SCD subjects were Ab-
positive compared with 31% of CN, which more resembles the
ﬁndings in our cohort23. Finally, we did not include an AD
dementia group, since we know from a previous study that
patients with severe AD dementia have lower CSF Ab40 than
patients with mild dementia (this may reﬂect reduced capacity to
produce Ab peptides as the disease progresses)24. Including an
AD dementia group in this study would therefore risk
confounding the relationship between CSF Ab40 and PET Ab.
Until now, there have been few attempts to examine the
independent roles of APOE e4 and APP processing in the
development of brain Ab pathology in non-demented subjects.
Previous studies did not ﬁnd correlations between CSF Ab40 (or
Ab38) and PET Ab (ref. 12). This is likely because they did not co-
vary for APOE e4 (and/or CSF Ab42). Adjusting for APOE e4 is
important since the relationship between CSF Ab40 and PET Ab
differs between APOE e4-positive and -negative individuals.
Furthermore, adjusting for APOE e4 and CSF Ab42 reduces the
residual errors of the models, and some of this error may contribute
to the variance of CSF Ab40. Once this error is removed the
correlation between CSF Ab40 and PET Ab can be better
estimated. Our results add novel information and point to
different possible pathways to Ab pathology in humans. In sum,
our results support the idea that sporadic Ab accumulation may be
partly associated with increased amyloidogenic APP production,
especially in APOE e4-negative subjects. The risk for sporadic AD
may consequently depend on increased Ab production, in addition
to decreased Ab clearance. This provides novel insight into disease
mechanisms in AD and may be important for development of
drugs targeting Ab metabolism in early stages of AD.
Methods
Study population. The study population came from the Swedish BioFINDER
study (Biomarkers For Identifying Neurodegenerative Disorders Early and
Reliably). All available CN and non-demented patients with mild cognitive
symptoms characterized as having SCD or MCI were included.
CN subject were originally enrolled from the population-based EPIC cohort. The
inclusion criteria were: age Z60 years old, MMSE 28-30, and ﬂuent in Swedish.
Exclusion criteria were: presence of subjective cognitive impairment, signiﬁcant
neurologic disease (for example, stroke, Parkinson’s disease, multiple sclerosis),
severe psychiatric disease (for example, severe depression or psychotic syndromes),
dementia or MCI. All CN subjects underwent a thorough clinical assessment,
including neurological, psychiatric and cognitive testing all performed by a medical
doctor, in addition to MRI of the brain and relevant blood tests. The cognitive
battery included MMSE, ADAS-cog (items 1–3), Trail Making A & B, Symbol Digit
modalities, A quick test of cognitive speed, clock drawing, cube coping, letter S
ﬂuency and animals ﬂuency. The medical doctor made a global assessment of
whether the individual was cognitively healthy based on the test results in relation to
education and age. All CN subjects had a Clinical Dementia Rating scale score of 0.
The SCD and MCI cases were recruited consecutively and were thoroughly
assessed by physicians with special competence in dementia disorders. The inclusion
criteria were: referred to a memory clinic due to possible cognitive impairment, not
fulﬁlling the criteria for dementia, MMSE 24–30, age 60–80 years and, ﬂuent in
Swedish. The exclusion criteria were: cognitive impairment that without doubt could
be explained by another condition (other than prodromal dementia); severe somatic
disease; and refusing lumbar puncture or neuropsychological investigation. The
classiﬁcation in SCD or MCI was based on a neuropsychological battery and the
clinical assessment of a senior neuropsychologist. The battery included tests for
verbal ability (including A multiple-choice vocabulary test (SRB:1 (ref. 25) and
semantic verbal ﬂuency (Condition 2, D-KEFS (ref. 26), episodic memory (including
Rey Auditory Verbal Learning Test (RAVLT (ref. 27), and Rey Complex Figure Test
(RCFT (ref. 28)), visuospatial construction ability (including Block design (WAIS
(ref. 29) and The copy trial of Rey Complex Figure Test), attention and executive
functions (including Trail Making Test (D-KEFS (ref. 26) and Letter Verbal Fluency,
Condition 1 (D-KEFS (ref. 26)). A senior neuropsychologist stratiﬁed all patients
into those with SCD (no measurable cognitive deﬁcits) or MCI according to the
consensus criteria for MCI suggested by Petersen30.
The Regional Ethics Committee in Lund, Sweden, approved the study.
All subjects gave written informed consent. For more details, see ref. 13 and
www.bioﬁnder.se.
PET analysis. Brain Ab was measured using 18F-ﬂutemetamol PET (refs 31,32).
PET/CT scanning was conducted at two sites using the same type of scanner, a
Philips Gemini TF 16. PET sum images from 90 to 110min post injection were
generated for the average uptake. MRI results were not used since this does not
improve the quantiﬁcation of 18F-ﬂutemetamol data33. The images were analysed
using the NeuroMarQ software provided by GE Healthcare. A volume of interest
template was applied for nine bilateral regions (prefrontal, parietal, lateral
temporal, medial temporal, sensorimotor, occipital, anterior cingulate and
posterior cingulate/precuneus), combined in a global neocortical composite
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Figure 3 | CSF Ab40 in different combinations of PET Ab and APOE e4.
Observed CSF Ab40 for different combinations of APOE e4 and PET Ab
positivity and negativity. The individual observations are overlaid on
boxplots (thick lines are medians, box limits are 25th and 75th percentiles).
CSF Ab40 was signiﬁcantly increased in the PET Abþ & APOE e4 group
compared with PET Ab- & APOE e4 , which was the reference category
(P¼0.015, using linear regression adjusted for age, sex, diagnosis and
WML). No other group had signiﬁcant different CSF Ab40 compared with
the PET Ab- & APOE e4 group (P¼0.62–0.90). The groups were PET
Ab- & APOE e4 , N¼ 158; PET Ab- & APOE e4þ , N¼ 39; PET Abþ &
APOE e4 , N¼41; and PET Abþ & APOE e4þ , N¼ 75. The total N¼ 313
for this analysis was smaller than the total study population (N¼ 331) due
to missing data for WML in 18 subjects (but the main results did not differ
when WMLwas not included and the analysis was done on the whole study
population). One data point is excluded from the graph for visual clarity
(CSF Ab40 14110 ng l 1, PET Abþ & APOE e4 ).
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signal33. The SUVR was the global composite tracer uptake, normalized for
the mean uptake in the cerebellar cortex (note that Thurfjell et al.35 found that
18F-ﬂutemetamol PET SUVR had 498% concordance with visual reads
independent of which reference region that was used). Most analyses in this study
used continuous PET Ab but when indicated a previously deﬁned cutoff for Ab
positivity was used (41.42 SUVR, based on mixture modelling analysis13).
Cerebrospinal ﬂuid analysis. All subjects underwent lumbar CSF sampling at
baseline, following the Alzheimer’s Association Flow Chart35. Samples were stored in
1ml polypropylene tubes at  80 C until analysis. CSF Ab38, Ab40 and Ab42 were
analysed by ELISA assays (EUROIMMUN AG, Lu¨beck, Germany). All analyses were
performed by board-certiﬁed laboratory technicians who were blinded for clinical
data and diagnoses. The CSF samples were randomized to avoid group bias. The
analyses were performed during two different runs in batch, plates 1–20 using lot no.
E140224AB for Ab38, E130611AA for Ab40 and E130607AA for Ab42, and plates
21–24 using lot no. E150522BK for Ab38, E150302A1 for Ab40 and E150522AZ for
Ab42. Aliquots of two different pools of CSF were used as internal control samples,
with CVs of 13.8% for Ab38 for the ﬁrst control with a mean of 695 pgml 1 and
7.9% for Ab38 for the second control with a mean of 1596 pgml 1; 17.9% for Ab40
for the ﬁrst control with a mean of 1951 pgml 1 and 11.1% for Ab40 for the second
control with a mean of 3992 pgml 1; and 16.3% for Ab42 for the ﬁrst control with a
mean of 227 pgml 1 and 15.1% for Ab42 for the second control with a mean of
216 pgml 1. To assure consistency in levels between the two runs, 40 CSF samples
from the ﬁrst run were re-analysed in the second run.
Plasma analysis. For plasma collection, blood was drawn into tubes containing
EDTA as anticoagulant. After centrifugation (2000g, þ 4 C, 10min), plasma
samples were aliquoted into polypropylene tubes and stored at  80 C pending
biochemical analyses. Plasma Ab40 was analysed using Simoa immunoassay
(Quanterix, Lexington, MA, USA).
White matter lesions. All patients were examined using a single 3T MR scanner
(Trio, Siemens). Automated segmentation of WML was performed using the Lesion
Segmentation Tool implemented in SPM8 (http://www.applied-statistics.de/lst.html),
generating a total WML volume. Before this, manual segmentation for reference of
WML was performed on FLAIR images co-registered to the native MPRAGE in four
MCI patients, with the segmented volume ranging from 0.5 to 106.3ml; the resulting
optimal k based on the Dice coefﬁcient was 0.4 (ref. 36) and was used in the
subsequent automated segmentation for all participants.
Statistical analysis. We tested correlations between CSF Ab40 and PET Ab in
different regression models. The main model was a linear regression model where
the dependent variable was PET Ab and the independent variables were CSF Ab40,
APOE e4 (dichotomous), and the interaction between CSF Ab40 and APOE e4.
Second, we tested the correlation between clinically signiﬁcant PET Ab
accumulation and CSF Ab40 and APOE e4 in a logistic regression model with PET
Ab positivity as the dependent variable. Third, we tested a linear regression model
with CSF Ab40 as the dependent variable and a four level combination of PET Ab
and APOE e4 as the independent variable (PET Ab- & APOE e4 , PET Ab- &
APOE e4þ , PET Abþ & APOE e4 and PET Abþ & APOE e4þ ). All models
were adjusted for age (years), sex and diagnostic group. We also adjusted for CSF
Ab42 to test if CSF Ab40 was associated with PET Ab beyond CSF Ab42, and to
reduce the residual error of the model, allowing a better estimate of the correlation
between CSF Ab40 and PET Ab. We adjusted for WML (ml) except for when
WML was clearly nonsigniﬁcant, as detailed in the results section. The primary
analyses were done using CSF Ab40, but we also performed analyses using CSF
Ab38 and a combination of CSF Ab38 and Ab40 (based on their molar weights,
Ab38: 4129.012 gmol 1; and Ab40: 4327.148 gmol 1 (ref. 37). Statistical
signiﬁcance was determined at Po0.05. All analyses were done using R
(v. 3.0.1, The R Foundation for Statistical Computing).
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